Fingolimod in Greek patients with relapsing-remitting MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tracks how Greek patients with relapsing-remitting multiple sclerosis (RRMS) respond to fingolimod (Gilenya) over time. By collecting data from your routine care, researchers hope to learn more about the real-world effectiveness and safety of this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- You are taking or will be taking fingolimod (Gilenya) as prescribed by your doctor.
- Your doctor has said fingolimod is safe for you (no medical reasons against it).
- You have medical records from the past year showing how many MS relapses you had.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors decide on the best MS treatment for you using an AI decision-support tool. You'll be part of a real-world evaluation of how this tool works when doctors are considering changing your MS medication.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This trial studies whether fingolimod can improve diabetes in adults with type 2 diabetes who are not yet on many medications. It will mainly check whether the drug is safe and whether it can help control blood sugar over time.
Hear when a new Relapsing Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.